This contract expires in 188 days (Dec 14, 2026).
PPD DEVELOPMENT LP - DAIDS MONITORING FOR 1 PHASE III STUDY: A5300B/I2003B (PHOENIX)
Key Details
Description
DAIDS MONITORING FOR 1 PHASE III STUDY: A5300B/I2003B (PHOENIX)
Context & Analysis
On Dec 10, 2025, Department of Health and Human Services obligated $3,092,829 to PPD DEVELOPMENT LP for daids monitoring for 1 phase iii study: a5300b/i2003b (phoenix). The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a cost plus fixed fee contract. Competition extent: full and open competition. Performance is located in WILMINGTON, NC. The contract is scheduled through Dec 14, 2026 — approximately 6 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541714 — related awards are listed below.
Contractor Information
Similar Awards
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ALLUCENT GOVERNMENT SERVICES (US) LLC
$370.1M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC.
$330.2M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
TECHNICAL RESOURCES INTERNATIONAL, INC.
$317.1M
ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION
PARATEK PHARMACEUTICALS, INC
$265.3M
ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA
GENENTECH INC
$243.7M
Stay Updated
Get notified about new opportunities matching your interests.